SMARCA2 and hematologic disorder: Additionally, a novel SMARCA4/SMARCA2 inhibitor, FHD-286, is being evaluated in a phase 1 dose escalation study in patients with advanced hematologic malignancies (ClinicalTrials.gov ID NCT04891757).